Robert Zibelman, MD
Psychiatry · Huntingdon Valley, PANPI 1669402871
Payments from drug & device makers
Across 362 payments — averaging $59.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Corium, LLC$576
- Lundbeck LLC$546
- Supernus Pharmaceuticals, Inc.$500
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$475
- Takeda Pharmaceuticals U.S.A., Inc.$365
- plus $1K from 8 others
What the payments were for
- Speaking & faculty fees$16,38076%
- Travel & lodging$5232%
- Food & beverage$4,52021%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 183 | $18,017 |
| Corium, LLC | 28 | $576 |
| Lundbeck LLC | 70 | $546 |
| Supernus Pharmaceuticals, Inc. | 1 | $500 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $475 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $365 |
| Otsuka America Pharmaceutical, Inc. | 7 | $326 |
| Axsome Therapeutics, Inc. | 8 | $281 |
| Neos Therapeutics, LP | 20 | $210 |
| Shire North American Group Inc | 5 | $74 |
| Johnson & Johnson | 2 | $51 |
| Ironshore Pharmaceuticals Inc. | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,482 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 56 | $2,403 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 82 | $2,161 |
| Bupropion XlBupropion Hcl | 97 | $2,129 |
| Olanzapine | 54 | $1,770 |
| Clonazepam | 96 | $1,677 |
| Methylphenidate Hcl | 32 | $1,288 |
| Alprazolam | 147 | $765 |
| Escitalopram Oxalate | 47 | $675 |
| Fluvoxamine Maleate | 12 | $630 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $580 |
| Bupropion Hcl SrBupropion Hcl | 26 | $470 |
| Lamotrigine | 45 | $462 |
| Methylphenidate Hcl Er (Cd)Methylphenidate Hcl | 12 | $383 |
| Gabapentin | 26 | $379 |
| Mirtazapine | 32 | $344 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Huntingdon Valley
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.